| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41397-019-0092-2 |
| P698 | PubMed publication ID | 31383939 |
| P50 | author | Chuenjid Kongkaew | Q54086979 |
| Manupat Lohitnavy | Q58795102 | ||
| P2093 | author name string | C N Scholfield | |
| Suphat Subongkot | |||
| Wimonchat Tangamornsuksan | |||
| P2860 | cites work | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q21092360 |
| Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis | Q26853305 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis | Q28080609 | ||
| The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01 | Q28548544 | ||
| Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity. | Q30238992 | ||
| Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial | Q30758991 | ||
| HLA-B*5701 screening for hypersensitivity to abacavir | Q34747145 | ||
| Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis | Q34864142 | ||
| Lapatinib-induced hepatitis: a case report. | Q34993721 | ||
| Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury | Q35136429 | ||
| Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations | Q35254140 | ||
| A review on the design and reporting of studies on drug-gene interaction | Q36153600 | ||
| Lapatinib: current status and future directions in breast cancer | Q36655753 | ||
| Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases | Q37274044 | ||
| Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials | Q37577947 | ||
| Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience | Q37677684 | ||
| Lapatinib for breast cancer: a review of the current literature | Q37810946 | ||
| Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial | Q38067005 | ||
| Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives | Q38101884 | ||
| A systematic review of dual targeting in HER2-positive breast cancer | Q38147686 | ||
| Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review | Q38268600 | ||
| Drug Hepatotoxicity: Newer Agents | Q39008339 | ||
| A method for meta-analysis of molecular association studies | Q45165474 | ||
| HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer | Q46575159 | ||
| Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes | Q46847041 | ||
| Association Between HLA genotypes and Oxcarbazepine-induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-Analysis. | Q49686482 | ||
| Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population | Q57557226 | ||
| Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes | Q83492372 | ||
| Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-analysis | Q88062255 | ||
| Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis | Q91640338 | ||
| P433 | issue | 1 | |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | 47-56 | |
| P577 | publication date | 2019-08-06 | |
| P1433 | published in | The Pharmacogenomics Journal | Q10534704 |
| P1476 | title | HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis | |
| P478 | volume | 20 |
| Q96816310 | HLA genotypes and cold medicine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications: a systematic review and meta-analysis | cites work | P2860 |
Search more.